Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Robert Risinger, MD
BioXcel Therapeutics
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Bioxcel Clinical Research Site
Anaheim, California, United States
Recruiting - Bioxcel Clinical Research Site
Hialeah, Florida, United States
Recruiting - Bioxcel Clinical Research Site
Atlanta, Georgia, United States
Completed - Bioxcel Clinical Research Site
Decatur, Georgia, United States
Recruiting - Bioxcel Clinical Research Site
DeSoto, Texas, United States
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 27 Aug 2021
- Primary completion
- 31 Jul 2027
- Completion
- 31 Dec 2027
- Last update posted
- 13 Apr 2026
- Registered enrollment
- 140
- Registry id
- NCT05025605
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.